Efficacy and Safety Study of Inhaled Glutathione in Cystic Fibrosis Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Cystic Fibrosis
Interventions
DRUG

reduced glutathione sodium salt

646 mg GSH-Na powder per vial to prepare a 4ml solution, twice daily for 24 weeks.

DRUG

0.9% normal saline (control)

4 ml of a 0.9% normal saline solution (9mg/ml NaCl), twice daily for 24 weeks.

Trial Locations (14)

13353

Charité Campus Virchow Klinikum,Klinik für Pädiatrie, Berlin

22763

Gemeinschaftspraxis CF Ambulanz, Hamburg

30625

Med. Hochschule Hannover, Hanover

44791

Universitätskinderklinink, Bochum

45239

Ruhrlandklinink, Essen

48153

Clemenshospital GmbH,Akademisches Lehrkrankenhaus der Westfälischen Wildhelms-Universität Münster, Münster

79104

Universitätsklinikum Freiburg, Freiburg im Breisgau

80336

Klinikum Innenstadt, Medizinische Klinik / Pneumologie, München

D-50924

Uniklinik Köln Mukoviszidose Zentrum, Cologne

D-45128

CF-Ambulanz/ Universitätsklinikum Essen, Essen

D-60590

CF-Ambulanz Frankfurt, Frankfurt

D-30625

MHH Kinderklinik CF-Ambulanz, Hanover

04109

Universitätsklinik, Leipzig

D-80337

CF-Amulanz/ Dr.von Haunersches Kinderspital, Munich

All Listed Sponsors
collaborator

Cystic Fibrosis Foundation

OTHER

lead

Mukoviszidose Institut gGmbH

OTHER

NCT00506688 - Efficacy and Safety Study of Inhaled Glutathione in Cystic Fibrosis Patients | Biotech Hunter | Biotech Hunter